In B-lymphoblastic leukemia/lymphoma patients who have received immunotherapeutic agents that target CD19, such as Blinatumomab and anti-CD19 chimeric antigen receptor cells (CAR-Ts), the blasts may exhibit decreased or absent CD19 at the time of disease relapse [18,19]. The gene discussed is CD19; the disease is lymphoma.